ConductScience.org, home
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
API referenceFor AI assistants

Trial · NCT03156621

Results by group54

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 54

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand)Placebo in DBTP8.6Standard Error 6.3Percentage of change
Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand)Alirocumab 150 mg SC Q2W-26.9Standard Error 4.6Percentage of change
Percent Change in Apolipoprotein (Apo) B From Baseline to Week 12 (ITT Estimand)Placebo in DBTP7.2Standard Error 5.0Percentage of change
Percent Change in Apolipoprotein (Apo) B From Baseline to Week 12 (ITT Estimand)Alirocumab 150 mg SC Q2W-22.5Standard Error 3.7Percentage of change
Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 12Placebo in DBTP8.0Standard Error 5.9Percentage of change
Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 12Alirocumab 150 mg SC Q2W-24.8Standard Error 4.3Percentage of change
Percent Change in Total Cholesterol (TC) From Baseline to Week 12Placebo in DBTP6.6Standard Error 5.0Percentage of change
Percent Change in Total Cholesterol (TC) From Baseline to Week 12Alirocumab 150 mg SC Q2W-19.8Standard Error 3.7Percentage of change
Percentage of Participants With ≥15% Reduction in LDL-C at Week 12Placebo in DBTP12.5Percentage of participants
Percentage of Participants With ≥15% Reduction in LDL-C at Week 12Alirocumab 150 mg SC Q2W61.9Percentage of participants
Percentage of Participants With ≥30% Reduction in LDL-C at Week 12Placebo in DBTP4.2Percentage of participants
Percentage of Participants With ≥30% Reduction in LDL-C at Week 12Alirocumab 150 mg SC Q2W57.1Percentage of participants
Percent Change in Lipoprotein(a) [Lp(a)] From Baseline to Week 12Placebo in DBTP8.8Standard Error 5.4Percentage of change
Percent Change in Lipoprotein(a) [Lp(a)] From Baseline to Week 12Alirocumab 150 mg SC Q2W-19.6Standard Error 4.0Percentage of change
Percentage of Participants With ≥50% Reduction in LDL-C at Week 12Placebo in DBTP0Percentage of participants
Percentage of Participants With ≥50% Reduction in LDL-C at Week 12Alirocumab 150 mg SC Q2W26.7Percentage of participants
Percent Change in HDL-C From Baseline to Week 12 - ITT AnalysisPlacebo in DBTP2.7Standard Error 3.1Percentage of change
Percent Change in HDL-C From Baseline to Week 12 - ITT AnalysisAlirocumab 150 mg SC Q2W6.3Standard Error 2.3Percentage of change
Percent Change in Fasting Triglycerides (TG) From Baseline to Week 12Placebo in DBTP3.9Standard Error 5.7Percentage of change
Percent Change in Fasting Triglycerides (TG) From Baseline to Week 12Alirocumab 150 mg SC Q2W-7.4Standard Error 4.2Percentage of change

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03156621/results

API referenceFor AI assistants